TICKERNERD
Menu
SPROSPROHealthcare · Biotechnology

SPRO Stock Forecast: Spero Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.11
−5.13% on the day

The 2 Wall Street analysts covering Spero Therapeutics, Inc. hold a median 12-month price target of $5 — +350.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$68.1M
Ticker Nerd rank
87/ 100
Median analyst target
$5.00
Analysts covering
2
Revenue$0.0−100.0% y/y
Operating income−$9.9M
Net income−$9.6M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.8%
1M
−7.5%
YTD
−52.4%
1Y
−52.4%
From 52W high
−62.8%
From 52W low
+3.7%
$1.07
$2.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SPRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Spero Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
87/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
98
Accruals
90
Size
78
Issuance
74
Volatility
62
Quality
58
Revisions
33
Momentum
25

Growth (99): Sales and profits are climbing, and climbing faster than before.

Momentum (25): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SPRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26SPROHigh $6.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $4.00Median $5.00High $6.00

The green dot is the last close — the median target sits +350.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Oct 2026Cantor FitzgeraldInitiatesOverweight$6.00
14 Sept 2026HC Wainwright & Co.MaintainsBuy$5.00 → $6.00
30 Jan 2025HC Wainwright & Co.ReiteratesBuy$5.00
30 Jan 2025HC Wainwright & Co.ReiteratesBuy—
20 Dec 2024Evercore ISI GroupDowngradeIn-Line—
2 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024TD CowenDowngradeHold—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Cantor FitzgeraldReiteratesOverweight—
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024TD CowenUpgradeBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024Cantor FitzgeraldReiteratesOverweight—
18 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
5 Sept 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
1 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SPRO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SPRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Spero Therapeutics, Inc. returned −52.4% against +13.6% for the S&P 500, dividends included.

SPRO vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26SPROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−186.6%
Analysts raising
0
Analysts cutting
0
Fundamentals

Spero Therapeutics, Inc. (SPRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.4×

Cheaper than 61% of US stocks

Price / sales
1.4×

Cheaper than 60% of US stocks

Price / book
1.5×

Cheaper than 52% of US stocks

EV / EBITDA
2.4×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
14.1%

Higher than 71% of US stocks

Net margin
15.7%

Higher than 78% of US stocks

Returns & dividend
Return on equity
19.2%

Higher than 80% of US stocks

Return on assets
7.2%

Higher than 86% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Spero Therapeutics, Inc. (SPRO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spero Therapeutics, Inc. has a market value of $68.1M and an enterprise value of $19.4M.

  • Revenue in the twelve months to 30 June 2026: $43.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $7.4M, a 17.2% net margin.

  • Diluted earnings per share, trailing twelve months: $0.11.

  • Free cash flow in the twelve months to 30 June 2026: $19.6M.

  • Shares outstanding: 58.1M.

  • Trailing P/E: 8.4×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Spero Therapeutics, Inc. employs 25 people — $1.7M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

SPRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPROSpero Therapeutics, Inc.$68.1M87
OSTXOS Therapies, Inc.$65.4M39
GOSSGossamer Bio, Inc.$65.3M53
FBIOFortress Biotech, Inc.$65.1M71
RNXTRenovoRx, Inc.$64.2M46
CSBRChampions Oncology, Inc.$67.8M27
CRDFCardiff Oncology, Inc.$69.2M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Spero Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPRO news & analysis

This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga · 28 Oct 2026positive

Benzinga’s headline reports that an analyst began coverage of Spero Therapeutics on a bullish note, as part of a roundup of five analyst initiations for Wednesday. The excerpt does not identify the analyst or provide details of the rating.

Why it matters — The initiation marks a new analyst outlook on SPRO, though the excerpt gives no supporting rationale or further details.

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

GlobeNewsWire · 26 Oct 2026positive

Spero Therapeutics appointed Amy Rock, Ph.D., as Chief Regulatory and Quality Officer. The announcement cites her experience in global regulatory strategy, clinical development, and approvals of novel immunotherapies.

Why it matters — The leadership appointment is relevant to SPRO watchers because it adds regulatory and quality expertise as the company advances its immunology pipeline.

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

GlobeNewsWire · 15 Oct 2026neutral

Spero Therapeutics said CEO Esther Rajavelu will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference in New York City on October 20, 2026. The company’s leadership team will also be available for one-on-one meetings.

Why it matters — The conference provides an opportunity for investors and other attendees to hear from Spero’s CEO and meet with its leadership team.

Russian plague outbreak could boost these under-the-radar pharma stocks

Invezz · 5 Oct 2026positive

A researcher at an anti-plague facility in Siberia's Irkutsk region died after exposure to Yersinia pestis, prompting Russian officials to quarantine regional hospitals and isolate nearly 200 contacts.

Why it matters — The outbreak could heighten attention on under-the-radar biopharma and infectious-disease companies, a space where SPRO watchers would find relevance.

FAQ

Frequently asked questions about SPRO stock

What is the SPRO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Spero Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRO stock a buy right now?

Of the 2 analysts covering Spero Therapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spero Therapeutics, Inc. 87 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRO?

As at 28 Oct 2026, Spero Therapeutics, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will SPRO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +350.5% from the last close, and Ticker Nerd's factor model ranks Spero Therapeutics, Inc. 87 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRO stock forecast for 2030?

No analyst covering Spero Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has SPRO stock performed over the past year?

Spero Therapeutics, Inc. returned -52.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spero Therapeutics, Inc. do?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is the latest news on SPRO?

The most recent item we track (Benzinga, 28 Oct 2026): "This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday". Benzinga’s headline reports that an analyst began coverage of Spero Therapeutics on a bullish note, as part of a roundup of five analyst initiations for Wednesday. The excerpt does not identify the analyst or provide details of the rating.

Company

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.

CEO Ms. Esther P. Rajavelu · 25 employees · United States · https://sperotherapeutics.com